重组人血管内皮抑素联合吉西他滨顺铂方案治疗转移性三阴性乳腺癌的疗效观察  

Observation on the effects of recombinant human endostatin combined with GP regimen in the treatment ofmetastatic three negative breast cancer

作　　者：张宁玲[1] 李秋梅[1] 

机构地区：[1]四川省南充市川北医学院附属医院,南充637000

出　　处：《中国肿瘤临床与康复》2014年第4期436-439,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨重组人血管内皮抑素联合吉西他滨顺铂(GP)方案治疗转移性三阴性乳腺癌(TNBC)的临床疗效和安全性。方法选取2009年1月至2013年3月间收治的58例转移性三阴性乳腺癌患者,随机分为重组人血管内皮抑素联合GP方案治疗组(A组,30例)和单纯GP方案治疗组(B组,28例),观察两组患者的近期、远期疗效和不良反应。结果 A组患者总有效率(RR)和疾病控制率(DCR)与B组患者比较,差异无统计学意义(P>0.05)。两组患者疾病进展时间(TTP)和中位生存时间(MST)差异有统计学意义(P<0.05)。两组患者不良反应发生率差异无统计学意义(P>0.05)。结论重组人血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌患者疗效较好,可延长患者生存时间,同时不良反应无明显增加,值得临床推广应用。Objective To investigate the clinical efficacy and safety of recombinant human en- dostatin combined plus GP regimen in the treatment of metastatic three negative breast cancer （TNBC）. Methods 58 metastatic three negative breast cancer patients admitted to our hospital from January 2009 to March 2013 were selected as observation objects, and were randomly divided into recombinant human en- dostatin combined with GP regimen intervention group （Group A, 30 cases） and GP regimen intervention group （Group B ,28 cases）. Recent effect,long-term effect and adverse reactions were observed. Results The difference of clinical efficacy and clinical benefit rate between group A and Group B was not significant （P 〉 0. 05 ）. The difference of time to progression （TI＇P） and the median survival time （MST） was statisti- cally significant （ P 〈 0. 05 ）. The incidence of adverse reaction in two groups was not significant different （P 〉 0.05 ）. Conclusion The efficacyof recombinant human endostatin combined with GP regimen in the treatment of patients with metastatic three negative breast cancer was good, prolong the survival time of pa- tients, and reduce adverse effect, which is worthy of clinical application.

关 键 词：重组人血管内皮抑素 GP方案 三阴性 转移性乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]